Racial and Ethnic Disparities in Gynecologic Carcinosarcoma: A Single-Institution Experience

Area of Science:

• Gynecologic Oncology
• Medical Malignancy Research

Background:

• Gynecologic carcinosarcoma is a rare, aggressive, and understudied malignancy.
• Understanding its incidence, treatment, and outcomes is crucial for improving patient care.

Purpose of the Study:

• To determine the incidence, treatment regimens, and treatment outcomes of gynecologic carcinosarcoma.
• To analyze progression-free survival (PFS) and overall survival (OS) in patients with this rare cancer.

Main Methods:

• Retrospective review of patients diagnosed and treated at a single tertiary care comprehensive cancer center (January 2012 - May 2021).
• Analysis of 84 identified cases of gynecologic carcinosarcoma (uterine, ovarian, cervical).
• Evaluation of patient demographics, disease stage, treatment protocols, PFS, and OS.

Main Results:

• Carcinosarcoma represented 5.2% of uterine, 3.6% of ovarian, and 0.28% of cervical cancers.
• 76.2% of patients presented with advanced-stage disease (Stage III/IV); minority patients were more likely to have advanced disease.
• Median PFS was 7.5 months; 55% and 45% of patients survived at 1 and 5 years, respectively.

Conclusions:

• Gynecologic carcinosarcoma is a rare malignancy often diagnosed at advanced stages.
• Standard treatment involves surgery followed by carboplatin and paclitaxel chemotherapy.
• Survival rates indicate a need for further research into more effective therapeutic strategies.